Literature DB >> 14756685

Oxcarbazepine antinociception in animals with inflammatory pain or painful diabetic neuropathy.

Sumiyoshi Kiguchi1, Takahiro Imamura, Kiyoshi Ichikawa, Masami Kojima.   

Abstract

1. Diabetic neuropathy is one of the most frequent complications of diabetes mellitus. However, the mechanisms underlying these disorders are not yet well defined and it has been reported that currently available analgesics have hardly any ameliorating effect on painful diabetic neuropathy. 2. The purpose of the present study was to evaluate the antinociceptive effect of oxcarbazepine (OCBZ), a keto derivative of carbamazepine (CBZ), in animal models generally used in pain research and in rats and mice with streptozotocin (STZ)-induced diabetes. In addition, we compared the effect of OCBZ with those of CBZ, mexiletine and morphine. 3. Diabetes was induced by injection of STZ at a dose of 300 mg/kg (i.p.) in mice and 50 mg/kg (i.v.) in rats. Experiments were conducted 2 weeks after STZ injection and those animals with a serum glucose level above 400 mg/dL were used for data analysis. Antinociceptive effects of the drugs were evaluated by the paw withdrawal test (normal, STZ-induced diabetic and carrageenin-injected rats), tail-flick test (normal and STZ-induced diabetic mice) and nociceptive behaviour (formalin-injected mice). 4. In the present study, diabetic mice showed thermal hyperalgesia and diabetic rats exhibited mechanical hyperalgesia. From these results, the STZ-induced diabetic animals used in the present study were found to be suitable for research on painful diabetic neuropathy. In STZ-induced diabetic animals, the antinociceptive effects of OCBZ, CBZ and mexiletine were facilitated, whereas the effect of morphine was attenuated, compared with effects in normal animals. 5. Oxcarbazepine inhibited the formalin-induced biphasic pain responses and increased the nociceptive threshold in the case of carrageenin-induced hyperalgesia. In view of these results, inhibition of substance P-mediated pain transmission may be involved in the antinociceptive action of OCBZ. 6. These results indicate that OCBZ has an analgesic action and is a possible therapeutic agent for the treatment of neuropathic pain, such as occurs in painful diabetic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756685     DOI: 10.1111/j.1440-1681.2004.03950.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  Regression of diabetic complications by islet transplantation in the rat.

Authors:  A Remuzzi; R Cornolti; R Bianchi; M Figliuzzi; C Porretta-Serapiglia; N Oggioni; V Carozzi; L Crippa; F Avezza; F Fiordaliso; M Salio; G Lauria; R Lombardi; G Cavaletti
Journal:  Diabetologia       Date:  2009-09-30       Impact factor: 10.122

2.  The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats.

Authors:  Georgia Gris; Enrique Portillo-Salido; Bertrand Aubel; Yassine Darbaky; Kristof Deseure; José Miguel Vela; Manuel Merlos; Daniel Zamanillo
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

3.  Alpha1A-adrenoceptor antagonist improves underactive bladder associated with diabetic cystopathy via bladder blood flow in rats.

Authors:  Saori Yonekubo; Satoshi Tatemichi; Kazuyasu Maruyama; Mamoru Kobayashi
Journal:  BMC Urol       Date:  2017-08-23       Impact factor: 2.264

4.  Characterization of Mechanical Allodynia and Skin Innervation in a Mouse Model of Type-2 Diabetes Induced by Cafeteria-Style Diet and Low-Doses of Streptozotocin.

Authors:  Gabriela Castañeda-Corral; Norma B Velázquez-Salazar; Arisai Martínez-Martínez; Juanita N Taboada-Serrano; Pablo N Núñez-Aragón; Laura González-Palomares; Rosa Issel Acosta-González; Vera L Petricevich; Juan José Acevedo-Fernández; Sergio Montes; Juan Miguel Jiménez-Andrade
Journal:  Front Pharmacol       Date:  2021-02-03       Impact factor: 5.810

5.  Expression of Toll-Like Receptor 4 in Glomerular Endothelial Cells under Diabetic Conditions.

Authors:  Shunsuke Takata; Yoshihiko Sawa; Takanobu Uchiyama; Hiroyuki Ishikawa
Journal:  Acta Histochem Cytochem       Date:  2013-02-15       Impact factor: 1.938

6.  Altered dynamics in the renal lymphatic circulation of type 1 and type 2 diabetic mice.

Authors:  Takanobu Uchiyama; Shunsuke Takata; Hiroyuki Ishikawa; Yoshihiko Sawa
Journal:  Acta Histochem Cytochem       Date:  2013-04-12       Impact factor: 1.938

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.